We're building the data integrity layer for regulated industries — life sciences, biotech, agritech, genomic research. We work with investors who understand that infrastructure for sensitive data is a category that takes patience, expertise and conviction.
For decades, data integrity in regulated industries has been treated as a documentation discipline — SOPs, validation reports, manual audit trails wrapped around systems built primarily for collection.
That model is breaking. Regulators across pharmaceuticals, agritech, public health and research are asking harder questions about the integrity of the underlying data, and most current systems cannot answer them cleanly.
The shift is creating demand for something that doesn't really exist yet: an infrastructure layer that makes data integrity continuous, verifiable and inspection-ready by default — without forcing organisations to rebuild their existing systems.
That is the opportunity The BioChain is built for.
Three things distinguish our position. The first is technical, the second is operational, the third is structural.
A snapshot of current activity. Specifics — metrics, named clients, commercial detail — are shareable under NDA.
Once we've spoken and a mutual NDA is in place, we share the full investor briefing pack.